APTO News and Press, Aptose Biosciences Inc. From 10/19/20

Aptose Biosciences ([[APTO]] +2.8%) announces dosing of the first patient with acute myeloid leukemia in a Phase 1 a/b clinical study with CG-806, the company’s oral kinase inhibitor.The investigational drug is the only known clinical agent that potently inhibits both FLT3 and BTK, giv...

SAN DIEGO and TORONTO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announce...

Aptose Biosciences (APTO) was initiated with a buy rating by Alliance Global Partners analyst Matt Cross, and gave a target price of $12, almost double from current level.Cross mentions in a research note, that the company's pipeline has seen "significant momentum" over the last several quart...

SAN DIEGO and TORONTO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, Presiden...

SAN DIEGO and TORONTO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, Presiden...

Editor's note: Seeking Alpha is proud to welcome Adam May as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Premium. Click here to find out more » With a recently depresse...

SAN DIEGO and TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President a...

Owning a biotech, particularly an early-stage biotech, can be a little like watching paint dry … while suspended very high up in the air and secured by a very thin cord. While management at Aptose ( APTO ) has been diligent about working with clinicians to keep its trials moving and a...

Aptose Biosciences Inc. (APTO) Q2 2020 Earnings Conference Call August 4, 2020 17:00 ET Company Participants Susan Pietropaolo - SMP Communications William Rice - Chairman, President & CEO Gregory Chow - EVP & CFO Rafael Bejar - SVP & CMO Jotin Marango - SVP &...

CG-806 Phase 1 a/b Study in B Cell Malignancies Advances to Fifth (750mg) Dose Cohort FDA Allows IND for Phase 1 a/b Study of CG-806 in AML to Initiate at 450mg Dose Level APTO-253 Phase 1b Study in AML / MDS Advances to Fifth (150mg/m 2 ) Dose Cohort Conference Call and Webc...